874-36-2

Usage

Uses

Used in Biochemical Research:
2,1,3-Benzoxadiazol-5-amine is used as a fluorescent label for nucleic acids, proteins, and lipids, facilitating the study of their structures, functions, and interactions at the molecular level.
Used in Cellular and Subcellular Structure and Function Studies:
2,1,3-Benzoxadiazol-5-amine is used as a fluorescent probe to investigate cellular and subcellular structures and functions, providing insights into various biological processes.
Used in Fluorescence Microscopy:
2,1,3-Benzoxadiazol-5-amine is used as a fluorescent marker in fluorescence microscopy, enabling the visualization of cellular components and processes with high resolution and specificity.
Used in Flow Cytometry:
2,1,3-Benzoxadiazol-5-amine is used as a fluorescent tag in flow cytometry, allowing for the rapid analysis and sorting of cells based on their fluorescence properties.
Used in Imaging Techniques:
2,1,3-Benzoxadiazol-5-amine is used as a fluorescent indicator in various imaging techniques, such as confocal microscopy and fluorescence resonance energy transfer (FRET), to study molecular interactions and dynamics in living cells.

Upstream product

• 18772-11-7 5-nitro-2,1,3-benzoxadiazole 
• 19155-88-5 benzo[c][1,2,5]oxadiazole-5-carboxylic acid 
• 36387-84-5 4-bromo-9-oxido-8-oxa-7,9-diazabicyclo[4.3.0]nona-1⁽⁹⁾,2,4,6-tetraene 
• 875-51-4 4-Bromo-2-nitroaniline 
• 51376-06-8 5-bromo-benzo[1,2,5]oxadiazole 

Downstream Products

• 1026305-49-6 N-[2-(2,1,3-benzoxadiazol-5-ylamino)-6-(2,6-dichlorophenyl)pyrido[2,3-d]pyrimidin-7-yl]-N'-(1,1-dimethylethyl)urea 

Relevant academic research and scientific papers

COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER

This disclosure relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to Heat Shock Transcription Factor 1 (HSF1) activity and/or function. More particularly, this disclosure relates to methods of inhibiting HSF1 activity with these compounds and pharmaceutical compositions thereof, and methods of treating diseases associated with HSF1 activity and/or function, such as cancer.

THIENODIAZEPINE DERIVATIVES AND APPLICATION THEREOF

The present invention relates to a class of thienodiazepine derivatives and an application thereof in the preparation of a drug for the treatment of diseases associated with bromodomain and extra-terminal (BET) Bromodomain inhibitors. Specifically, the present invention relates to compounds represented by formulas (I) and (II), as well as pharmaceutically acceptable salts thereof.

COMPOUNDS USEFUL AS CSF1 MODULATORS

This invention relates to novel compounds and to pharmaceutical compositions comprising the novel compounds. More specifically, the invention relates to compounds useful as Colony Stimulating Factor 1 Receptor (cFMS) modulators (e.g. cFMS inhibitors). This invention also relates to processes for preparing the compounds, uses of the compounds in treatment and methods of treatment employing the compounds. Specifically, the invention relates to the use of the compounds for the treatment of cancer and autoimmune diseases.

METHOD FOR THE PREPARATION OF FUSED HETEROCYCLIC SUCCINIMIDE COMPOUNDS AND ANALOGS THEREOF

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Fused heterocyclic succinimide compounds and analogs thereof, modulators of nuclear hormone receptor function

Fused cyclic compounds, methods of using such compounds in the treatment of nuclear hormone receptor-associated conditions such as cancer and immune disorders, and pharmaceutical compositions containing such compounds.

Photophysical study of 5-substituted benzofurazan compounds as fluorogenic probes

Nine 5-substituted benzofurazans including the non-substituted benzofurazan were synthesized, and measurements of the fluorescence, photolysis, transient absorption, and time-resolved thermal lensing signal were performed in order to understand the relaxation processes of these compounds. The results indicated that the main relaxation process was a photoreaction from an excited singlet state and the rate of the primary bond cleavage in the excited state tended to increase in the compound in which the S2←S0 absorption band is located close to the S1←S0 absorption band. These results suggest that the reactive state might be the S2 state, and that the interaction between the S1 and S2 states promotes the photoreaction. The separation of the S1 state from the S2 state decreases the rate of photoreaction, resulting in an increase in the Φf values. The Φf values of the 5-substituted benzofurazans in cyclohexane and acetonitrile were compared with their ΔE(S1, S2) (energy gap between the S1 and S2 states) values calculated by using a combination of AM1(EXCITED) and AM1-CAS/ CI(CI = 6) for geometric optimization and calculation of the energy levels, respectively. The ΔE(S1, S2) values correlated well with the Φf values in each solvent, thus enabling us to predict the fluorescence properties of the 5-substituted benzofurazans based on their chemical structures.